PCV chemotherapy for recurrent glioblastoma.

F Schmidt, J Fischer, U Herrlinger, K Dietz, J Dichgans, M Weller

Journal: Neurology 2006;66(4):587-9

PMID: 16505319

Abstract

The authors administered procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, lomustine), and vincristine (PCV) to 86 patients with recurrent glioblastoma. There were three partial responses, but no complete responses. Median progression-free survival was 17.1 weeks and progression-free survival at 6 months was 38.4%. World Health Organization grade III/IV hematologic toxicity was common (25.6%), but nonhematologic toxicity was mild.

Address: Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tuebingen, Medical School, Tuebingen, Germany. [email protected]

DOI: 10.1212/01.wnl.0000197792.73656.c2

Link outs

Free resources

Medical:

https://medlineplus.gov/braintumors.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Disease Progression, Disease-Free Survival, Female, Glioblastoma, Humans, Lomustine, Male, Middle Aged, Procarbazine, Recurrence, Time Factors, Vincristine